Mr. Mads Gamborg | Pharmacoepidemiology – PhD Fellow at Danish Cancer Society Research Center, Denmark
Mads Gamborg is an emerging leader in the field of public health and epidemiology, particularly in cancer and neurodegenerative disease research. As a PhD Fellow at the Danish Cancer Institute (DCI), part of the Danish Cancer Society, he brings together a strong academic foundation, rich interdisciplinary expertise, and an impressive publication record at the intersection of pharmacoepidemiology and public health. With a passion for precision medicine, health equity, and statistical modeling, Mads has contributed meaningfully to our understanding of how medications and public health dynamics interact in complex disease contexts. His work demonstrates both scientific rigor and a genuine commitment to societal health outcomes.
Academic Profile
Education
Mads’s educational trajectory reflects his dedication to bridging the fields of human physiology and public health. He earned a Bachelor of Science in Sport Sciences from Aalborg University, graduating with a strong GPA and top marks on his bachelor thesis. He proceeded to complete a Master of Science in Exercise Biology at Aarhus University, where his academic excellence continued, earning a GPA of 11.3 and a top-grade thesis (12). His academic progression culminated in his acceptance into the Doctor of Philosophy (PhD) program in Public Health and Epidemiology at the University of Copenhagen, where he is currently conducting advanced research on pharmacoepidemiological interventions, cancer outcomes, and neurological disease prevention using national registry-based studies.
Experience
Mads brings extensive hands-on research experience gained through progressive roles across top Danish research institutions. He began his research journey as a Student Assistant on the “Diet, Cancer and Health – Next Generations (DCH-NG)” cohort at the Danish Cancer Society, followed by a role as a Student Research Assistant at the Department of Public Health, Aarhus University. His work with the Research Unit for Health Promotion and Population Health enhanced his exposure to preventive strategies and large-scale cohort data. Between 2022 and 2023, Mads served as a Research Assistant at the Danish Cancer Institute, before transitioning into his current role as a PhD Fellow. These experiences have allowed him to contribute meaningfully to both academic and translational research projects, collaborate with cross-national teams, and deliver insights that bridge clinical, biological, and social perspectives in healthcare.
Research Interest
Mads’s research interests lie at the intersection of cancer epidemiology, neurological diseases, pharmacoepidemiology, and health inequality. He is particularly passionate about understanding the long-term effects of medications such as GLP-1 receptor agonists on cancer and neurological outcomes, including Parkinson’s disease. His work focuses on large-scale population-based cohort studies utilizing national health registries, which enables robust causal inference in real-world data settings. He also holds a keen interest in exploring underrepresentation in clinical trials and developing data-driven strategies to mitigate disparities in access to care and outcomes.
Award
Mads Gamborg was honored with the “Best Oral Presentation Award” at the 30-year Anniversary Meeting of the Danish Society of Pharmacoepidemiology (DSFE) in 2024 for his compelling research on “Underrepresented Groups in Clinical Trials.” This recognition not only highlights the academic strength of his work but also his ability to communicate complex epidemiological findings with clarity, impact, and policy relevance. His involvement as a teaching assistant and summer school organizer further showcases his dedication to academic service and peer development.
Publications
📘 2025 – “Long-term cancer risk in users of GLP-1 agonists in Denmark: a nationwide emulated trial,” The Lancet Regional Health – Europe – A pivotal study exploring cancer risk associated with GLP-1 medications, cited in articles on metabolic therapy and public health policy.
🧠 2025 – “GLP-1 Agonists as Potential Neuromodulators in Parkinson’s Disease,” European Journal of Neurology – A significant cohort study on neurological implications of diabetes drugs, referenced in neurology and epidemiology research.
📊 2024 – “Regional cancer incidence and survival in Denmark,” Cancer Epidemiology – A vital contribution to understanding geographical disparities in cancer care, cited by regional cancer strategy reviews.
🌍 2023 – Co-authored “Were cancer patients worse off during the COVID-19 pandemic?” The Lancet Regional Health – Europe – A cross-national analysis spanning Denmark, Norway, and Iceland, widely cited in pandemic impact studies.
👶 2023 – “In Utero Exposure to Hormonal Contraception and Mortality in Offspring,” Cancers (Basel) – A nuanced analysis of prenatal drug exposure and childhood mortality, cited in reproductive health literature.
📚 2022 – “Health literacy in the prenatal phase: A systematic review,” Sexual & Reproductive Healthcare – A foundational review shaping health education strategies, cited in maternal health studies.
💪 2022 – “Muscle Strength and Power in People With Parkinson Disease,” Journal of Neurologic Physical Therapy – A meta-analysis informing clinical rehab practices, referenced in Parkinson’s treatment guidelines.
Conclusion
Mads Gamborg represents the next generation of impactful health researchers whose work bridges the biological, clinical, and societal aspects of medicine. His early-career achievements—ranging from prestigious journal publications and speaking awards to leadership in academic training—demonstrate both promise and performance. His ability to navigate complex data, translate findings into public health relevance, and maintain collaborative and ethical standards make him highly deserving of the Best Researcher Award. With continued support and visibility, Mads is poised to become a thought leader in epidemiological research and a valuable contributor to global health improvement initiatives.